Hutchmed Regulatory News (HCM)

22 Jun 2007 07:00

Hutchison China Meditech Limited22 June 2007 Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Block Admission London: Friday, 22 June 2007: Chi-Med today announces that an application hasbeen made to London Stock Exchange plc for the block admission of 2,560,606 newordinary shares of US$1 each (the "New Shares") to trade on the AlternativeInvestment Market. The New Shares will represent approximately 5% of theexisting issued share capital of Chi-Med. Each of the New Shares may beallotted and issued in due course should options granted under Chi-Med's ShareOption Scheme be exercised. As at the date of this announcement, the issued share capital of Chi-Med isUS$51,212,121 comprising 51,212,121 ordinary shares of US$1 each. Ends Enquiries Chi-Med Telephone: +852 2121 8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle Mobile: +44 (0) 7973 611 888Yvonne Alexander Mobile: +44 (0) 7866 610 682 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock Exchange